Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst

2025-12-29 14:55:42 ET

The last time I spoke about Edgewise Therapeutics, Inc. ( EWTX ), it was in a Seeking Alpha article entitled "Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On." With respect to this article, I went over the company gearing up to release 12-week clinical trial data from its phase 2 CIRRUS-HCM study using its cardiac sarcomere modulator EDG-7500 for the treatment of patients with hypertrophic cardiomyopathy [HCM]. In essence, what I'm going to go over below specifically would be favorable interim safety results from Part D of this mid-stage study that the company had released. If this type of interim safety data was just released, then why should investors be keeping an eye on this name? It is simply because this positive interim safety update leads to two other major catalysts that could boost shareholder value. The first of which is that the company expects to release additional data again from this very same 12-week Part D phase 2 CIRRUS-HCM study in Q2 of 2026....

Read the full article on Seeking Alpha

For further details see: